All posts tagged "lenacapavir"

ViiV’s Cabotegravir Surpasses Gilead’s Lenacapavir in Early Trial

ViiV Healthcare has announced that its long-acting HIV pre-exposure prophylaxis (PrEP) therapy, cabotegravir, demonstrated superior acceptability among patients compared to Gilead Sciences‘ lenacapavir in an early-stage...